Loading...
Loading...
CRDF| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.1M |
| Operating Expense | 14.7M |
| Operating I/L | -14.8M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.8M |
| Pretax | -13.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -13.9M |
Cardiff Oncology, Inc. is a California-based clinical-stage oncology company specializing in developing innovative cancer treatments. The company's lead drug candidate, onvansertib, is an oral selective Polo-like Kinase 1 Inhibitor designed for anti-cancer therapeutics. Additionally, Cardiff Oncology's product pipeline includes CY140, a promising inhibitor of PLK1, PLK2, and PLK3, currently in phase 1/2 studies for solid tumors and leukemias, as well as clinical trials for metastatic colorectal cancer and TROV-054, a Phase 1b/2 drug for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers, positioning itself as a key player in the oncology drug development market.
